ABUS Arbutus Biopharma Corporation - Common Stock
$5,01
Prix · Aoû 19, 2026
Données fondamentales au Aoû 12, 2026
Fourchette 52 semaines
$3–$5
82% of range
Note des analystes
BUY
8 analysts
Objectif de cours
$6
+10% upside
P/E (TTM)
-30.1
ROE
-42.0%
Marge nette
-237.9%
À propos de Arbutus Biopharma Corporation - Common Stock Présentation de l'entreprise depuis Wikipedia
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
Lire la suite
Arbutus Biopharma Corporation is a publicly traded Canadian (NASDAQ: ABUS) biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007.
History
Tekmira, as the company was formerly called, was formed as a wholly owned subsidiary of Inex Pharmaceuticals in 2005 after that company began collapsing after its regulatory and partnering strategy failed in 2004. Tekmira was fully spun out in 2007 and Tekmira absorbed the assets of Inex, which had been founded in 1992.
Inex had been developing liposomal formulations of off-patent cancer drugs, and licensed them to Talon Pharmaceuticals in 2005; Talon was acquired by Spectrum Pharmaceuticals in 2013, and three former Inex/Tekmira products reached the market and began generating royalties for Tekmira: Marqibo (liposomal vincristine), Alocrest (liposomal vinorelbine) and Brakiva (liposomal topotecan).
Inex had also acquired licenses to intellectual property, as well as staff and manufacturing facilities, concerning RNAi technology from Lynx Therapeutics in 1998; this set of technologies became the focus for Tekmira and it initially sought to develop liposomally encapsulated RNAi drugs for a broad range of indications.
Tekmira also worked on providing liposomal delivery technology to other companies. In 2007 it signed a license agreement with Alnylam Pharmaceuticals so that Alnylam could use it to deliver its own RNAi drugs; that deal was expanded into a manufacturing agreement in 2009.
Most of those products not focused on viral diseases faltered, and Tekmira had only $6.3 million in cash when it filed suit against Alnylam in 2011 for breaching its contract and stealing trade secrets. The suit was settled in 2012, with Alnylam agreeing to pay Tekmira $65 million in termination fees, and the companies negotiated a new license agreement with lower milestones and royalties, which covers Alnylam's product patisiran.
Tekmira caught the world's attention and its stock rose dramatically during the 2013 West African Ebola virus epidemic due to its drug candidate for Ebola fever, TKM-Ebola. Tekmira was developing it under a $140 million US Department of Defense contract. While its stock was trading high in January 2015, it acquired OnCore BioPharma, a company focused on hepatitis B.
On December 19, 2014, Tekmira announced the appointment of former Bill & Melinda Gates Foundation CFO Richard Henriques to the company's board of directors. The company simultaneously announced the forthcoming departure of Ian MacLachlan as Executive Vice President and Chief Technical Officer.
Development of TKM-Ebola was terminated in mid June 2015 during a Phase II trial, for lack of efficacy.
The next month, Tekmira changed its name to Arbutus Biopharma and said that it would focus on drugs to treat hepatitis B.
In March 2017 Arbutus signed another license for its liposome delivery technology, this time with Alexion Pharmaceuticals, for delivery of an mRNA drug candidate. This license was terminated in July 2017, when Alexion discontinued preclinical programs outside its core complement franchise.
In 2019, Arbutus began a phase 1 clinical study using AB-506 to treat chronic hepatitis B. The company released preliminary data in July and stopped the trial in October after two patients developed acute hepatitis. Now AB-729 is paving the way for Arbutus, as they recently received the FDA go ahead to pursue phase 2 trials, after having their data voted best in ILC, 2021; after abandoning development of previous investigational agents. AB-836, Arbutus's next generation capsid inhibitor, has shown potential against mutants in its phase 1 trials.
In July 2019, Arbutus Biopharma announced the sale of part of its royalty interest on future global net sales of ONPATTRO, an RNA interference therapeutic currently sold by Alnylam Pharmaceuticals, to OMERS for $20 million.
COVID-19
On March 10, 2023, U.S. District Judge Mitchell Goldberg rejected a bid by Moderna to dismiss some of the patent infringement claims brought against the company by Arbutus and its partner, Genevant Sciences.
Moderna settled their lawsuit and will pay Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna’s Section 1498 appeal.
Source : Wikipedia (Anglais), CC BY-SA 4.0 · Voir sur Wikipedia ↗
ABUS Aperçu de l'action Prix, capitalisation boursière, P/E, EPS, ROE, dette/capitaux propres, fourchette sur 52 semaines
Prix
$5.01
Capitalisation Boursière
$987M
P/E (TTM)
-30.1
BPA (TTM)
$-0.17
Revenus (TTM)
$14M
Rendement div.
—
ROE
-42.0%
Dette/Capitaux propres
—
Fourchette 52 semaines
$3 – $5
ABUS Graphique du cours de l'action OHLCV quotidien avec indicateurs techniques — panoramique, zoom et personnalisez votre vue
Configure
Performance sur 10 ans Tendances du chiffre d'affaires, du bénéfice net, des marges et du BPA
Revenus et bénéfice net
$14M
2016-12-31
→
2025-12-31
BPA
$-0.17
2016-12-31
→
2025-12-31
Flux de trésorerie libre
$-40M
2016-12-31
→
2025-12-31
Marges
-237.9%
Valorisation Ratios P/E, P/S, P/B, EV/EBITDA — l'action est-elle chère ou bon marché ?
Métrique
Tendance sur 5 ans
ABUS
Médiane des pairs
P/E (TTM)
-30.1
6.7
P/S (TTM)
70.1
39.8
P/B
12.9
4.8
Price / FCF (Cours / FCF)
-24.9
—
Rentabilité Marges brutes, d'exploitation et nettes ; ROE, ROA, ROIC
Métrique
Tendance sur 5 ans
ABUS
Médiane des pairs
Operating Margin (Marge d'exploitation)
-271.0%
—
Net Profit Margin (Marge nette)
-237.9%
-220.1%
ROA
-29.6%
-35.0%
ROE
-42.0%
-43.2%
Santé financière Dette, liquidité, solvabilité — solidité du bilan
Métrique
Tendance sur 5 ans
ABUS
Médiane des pairs
Current Ratio (Ratio de liquidité)
15.7
9.7
Quick Ratio (Ratio de liquidité réduite)
15.5
—
Croissance Croissance du chiffre d'affaires, du BPA et du bénéfice net : Année/Année, TCAC 3 ans, TCAC 5 ans
Métrique
Tendance sur 5 ans
ABUS
Médiane des pairs
Revenue YoY (Chiffre d'affaires YoY)
128.2%
—
Revenue CAGR 3Y (CAGR du chiffre d'affaires 3 ans)
-28.8%
—
Revenue CAGR 5Y (CAGR du chiffre d'affaires 5 ans)
15.3%
—
Efficacité du capital Rotation des actifs, rotation des stocks, rotation des créances
Métrique
Tendance sur 5 ans
ABUS
Médiane des pairs
ABUS Consensus des analystes Opinions des analystes haussières et baissières, objectif de cours à 12 mois, potentiel de hausse
ACHAT
8 analystes
- Achat fort 3 37,5%
- Achat 4 50,0%
- Conserver 1 12,5%
- Vente 0 0,0%
- Vente forte 0 0,0%
Objectif de cours à 12 mois
1 analystes · 2026-08-17
Bas
$5.53
Haut
$5.53
Objectif médian
$5.53
+10,3%
Objectif moyen
$5.53
+10,3%
Historique des bénéfices BPA réel vs estimation, surprise %, taux de succès, prochaine date de publication des résultats
Surprise Moyenne
0.01%
| Période | EPS Actual | BPA est. | Surprise |
|---|---|---|---|
| 31 mars 2026 | $-0.05 | $-0.03 | -0.02% |
| 31 décembre 2025 | $-0.02 | $-0.04 | 0.02% |
| 30 septembre 2025 | $-0.04 | $-0.03 | -0.01% |
| 30 juin 2025 | $0.01 | $-0.05 | 0.06% |
| 31 mars 2025 | $-0.13 | $-0.11 | -0.02% |
| 31 décembre 2024 | $-0.07 | $-0.08 | 0.01% |
Comparaison des pairs (sous-secteur GICS) Indicateurs clés par rapport aux pairs du secteur
| Ticker | Capitalisation Boursière | P/E | Revenus Année/Année | Marge Nette | ROE | Marge Brute |
|---|---|---|---|---|---|---|
| ABUS | $926M | -28.3 | 128.2% | -237.9% | -42.0% | — |
| XENE | $3.59B | -10.3 | — | -4612.1% | -56.9% | — |
| AUPH | $2.11B | 7.7 | 20.4% | 101.5% | 62.7% | — |
| ZYME | $1.97B | -24.4 | 38.9% | -76.6% | -26.9% | — |
| ACOG | $141M | -5.5 | — | -202.2% | -43.8% | — |
Fondamentaux complets Tous les indicateurs par an — compte de résultat, bilan, flux de trésorerie
Compte de résultat 16
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14M | $6M | $18M | $39M | $11M | $7M | $6M | $6M | $11M | $1M | $23M | |
| R&D Expense | $25M | $54M | $74M | $84M | $66M | $49M | $58M | $58M | $63M | $61M | $52M | |
| SG&A Expense | $16M | $22M | $22M | $18M | $17M | $15M | $18M | $16M | $16M | $39M | $26M | |
| Operating Expenses | $52M | $82M | $96M | $104M | $85M | $65M | $150M | $96M | $122M | $493M | $127M | |
| Operating Income | $-38M | $-76M | $-78M | $-65M | $-74M | $-58M | $-144M | $-90M | $-111M | $-492M | $-104M | |
| Interest Expense | · | · | $459.0K | $2M | $3M | $4M | $2M | $226.0K | $261.0K | $0 | $0 | |
| Interest Income | $4M | $7M | $6M | $2M | $127.0K | $741.0K | $2M | $3M | $2M | $1M | $674.0K | |
| Other Non-op | $5M | $6M | $5M | $444.0K | $-3M | $-6M | $-22M | $28M | $2M | $2M | $25M | |
| Pretax Income | · | · | · | · | · | $-64M | $-166M | $-61M | $-109M | $-489M | $-79M | |
| Income Tax | $0 | $0 | $0 | $4M | $0 | $0 | $-13M | $-4M | $-24M | $-105M | $-16M | |
| Net Income | $-34M | $-70M | $-73M | $-69M | $-76M | $-64M | $-154M | $-57M | $-84M | $-384M | $-63M | |
| EPS (Basic) | $-0.17 | $-0.38 | $-0.44 | $-0.46 | $-0.83 | $-1.00 | · | $-1.21 | $-1.56 | $-7.24 | $-1.38 | |
| EPS (Diluted) | $-0.17 | $-0.38 | $-0.44 | $-0.46 | $-0.83 | $-1.00 | · | $-1.21 | $-1.56 | $-7.24 | $-1.38 | |
| Shares (Basic) | 191,599,600 | 185,608,874 | 165,960,379 | 150,939,337 | 106,242,452 | 75,835,378 | · | 55,304,083 | 54,723,272 | 53,074,401 | 45,462,324 | |
| Shares (Diluted) | 191,599,600 | 185,608,874 | 165,960,379 | 150,939,337 | 106,242,452 | 75,835,378 | · | 55,304,083 | 54,723,272 | 53,074,401 | 45,462,324 | |
| EBITDA | $-38M | $-76M | $-78M | $-65M | $-74M | $-58M | · | $-90M | $-111M | $-492M | · |
Bilan 25
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $18M | $36M | $26M | $31M | $109M | $52M | $32M | $37M | $54M | $23M | $167M | |
| Short-term Investments | $73M | $86M | $100M | $116M | $46M | $71M | $59M | $88M | $72M | $107M | $15M | |
| Receivables | $1M | $2M | $2M | $1M | $899.0K | $1M | $1M | $1M | $402.0K | $273.0K | $1M | |
| Prepaid Expense | $2M | $2M | $4M | $3M | $4M | $3M | $2M | $3M | $2M | $1M | $1M | |
| Current Assets | $94M | $127M | $132M | $151M | $161M | $128M | $94M | $129M | $129M | $133M | $184M | |
| PP&E (Net) | $32.0K | $3M | $5M | $5M | $6M | $7M | $9M | $10M | $12M | $7M | $3M | |
| PP&E (Gross) | $245.0K | $16M | $17M | $16M | $15M | $15M | $14M | $17M | $25M | $18M | $13M | |
| Accum. Depreciation | $213.0K | $13M | $12M | $11M | $9M | $8M | $6M | $7M | $13M | $11M | $10M | |
| Goodwill | · | · | · | · | · | · | $0 | $22M | $24M | $24M | $163M | |
| Intangibles | · | · | · | · | · | · | $0 | $44M | $59M | $99M | $353M | |
| Other Non-current Assets | $130.0K | $34.0K | $0 | $103.0K | $61.0K | $44.0K | $293.0K | $0 | · | · | · | |
| Total Assets | $95M | $132M | $144M | $195M | $204M | $137M | $106M | $228M | $237M | $276M | $712M | |
| Accounts Payable | $5M | $8M | $10M | $16M | $11M | $9M | $7M | $9M | $11M | $10M | $9M | |
| Current Liabilities | $6M | $16M | $22M | $33M | $11M | $10M | $8M | $11M | $15M | $11M | $11M | |
| Capital Leases | $199.0K | $806.0K | $1M | $2M | $2M | $3M | $3M | $0 | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | $0 | $13M | $17M | $41M | $146M | |
| Total Liabilities | $18M | $34M | $38M | $59M | $35M | $35M | $33M | $28M | $55M | $73M | $165M | |
| Long-term Debt | $0 | $0 | $0 | $0 | $0 | · | · | · | · | · | · | |
| Common Stock | $1.42B | $1.41B | $1.35B | $1.32B | $1.29B | $986M | $899M | $879M | $876M | $867M | $834M | |
| Paid-in Capital | $83M | $82M | $81M | $72M | $65M | $61M | $55M | $48M | $43M | $37M | $30M | |
| Retained Earnings | $-1.38B | $-1.35B | $-1.28B | $-1.20B | $-1.13B | $-1.05B | $-970M | $-805M | $-738M | $-653M | $-267M | |
| AOCI | $-48M | $-48M | $-48M | $-50M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-50M | |
| Stockholders' Equity | $77M | $97M | $106M | $137M | $169M | $102M | $73M | $200M | $182M | $203M | $548M | |
| Liabilities + Equity | $95M | $132M | $144M | $195M | $204M | $137M | $106M | $228M | $237M | $276M | $712M | |
| Shares Outstanding | 192,531,225 | 189,963,492 | 169,867,414 | 157,455,363 | 144,987,736 | 89,678,722 | 64,780,314 | 55,518,800 | 55,060,650 | 54,841,494 | 54,570,691 |
Flux de trésorerie 14
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $7M | $9M | $9M | $7M | $6M | $6M | $7M | $6M | $15M | · | · | |
| Deferred Tax | · | · | · | · | · | $0 | $-13M | $-4M | $-24M | $-105M | $-16M | |
| Restructuring | $13M | $4M | $0 | · | $0 | $64.0K | $156.0K | $5M | $0 | · | · | |
| Operating Cash Flow | $-40M | $-65M | $-86M | $-35M | $-68M | $-51M | $-71M | $-68M | $-49M | $-58M | $-56M | |
| CapEx | $0 | $182.0K | $1M | $512.0K | $809.0K | $229.0K | $589.0K | $1M | $7M | $4M | $2M | |
| Investing Cash Flow | $16M | $23M | $51M | $-75M | $-13M | $-15M | $28M | $-4M | $28M | $-99M | $8M | |
| Debt Issued | · | · | · | · | · | · | · | · | $0 | $12M | $0 | |
| Net Debt Issued | · | · | · | · | · | · | · | · | $0 | $12M | · | |
| Stock Issued | · | · | · | · | $135M | $86M | $19M | $0 | $0 | $0 | $142M | |
| Net Stock Activity | · | · | · | · | $135M | $86M | · | · | $0 | $0 | · | |
| Financing Cash Flow | $6M | $52M | $31M | $32M | $137M | $87M | $37M | $56M | $49M | $13M | $144M | |
| Net Change in Cash | $-18M | $10M | $-4M | $-79M | $57M | $20M | $-5M | $-17M | $31M | $-143M | $95M | |
| Free Cash Flow | $-40M | $-65M | $-87M | $-36M | $-68M | $-52M | · | $-69M | $-56M | $-62M | · | |
| Levered FCF | · | · | · | · | · | $-56M | · | $-69M | $-56M | · | · |
Rentabilité 7
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -271.0% | -1236.7% | -430.5% | -167.8% | -669.1% | -836.1% | · | -1510.2% | -1036.7% | -32973.8% | · | |
| Net Margin | -237.9% | -1133.0% | -401.6% | -178.0% | -693.9% | -922.0% | · | -959.8% | -788.9% | -25765.5% | · | |
| Pretax Margin | · | · | · | · | · | -922.0% | · | -1031.8% | -1016.2% | -32807.9% | · | |
| EBITDA Margin | -271.0% | -1236.7% | -430.5% | -167.8% | -669.1% | -836.1% | · | -1510.2% | -1036.7% | -32973.8% | · | |
| ROA | -29.6% | -50.6% | -42.9% | -34.7% | -44.6% | -52.5% | · | -24.5% | -32.9% | -77.8% | · | |
| ROE | -42.0% | -68.5% | -64.6% | -49.2% | -50.9% | -64.0% | · | -27.5% | -43.8% | -102.4% | · | |
| ROIC | · | · | · | · | · | -56.7% | · | -41.7% | -47.2% | -190.2% | · |
Liquidité et Solvabilité 3
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 15.7 | 8.2 | 5.9 | 4.6 | 14.3 | 13.4 | · | 11.5 | 8.8 | 12.5 | · | |
| Quick Ratio | 15.5 | 8.0 | 5.7 | 4.5 | 13.9 | 13.1 | · | 11.2 | 8.7 | 12.4 | · | |
| Interest Coverage | · | · | -170.2 | -37.9 | -25.7 | -14.4 | · | -397.3 | -425.0 | · | · |
Efficacité 2
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.0 | 0.1 | 0.2 | 0.1 | 0.1 | · | 0.0 | 0.0 | 0.0 | · | |
| Receivables Turnover | 7.3 | 2.9 | 11.6 | 34.7 | 9.9 | 5.5 | · | 6.5 | 31.7 | 2.3 | · |
Taux de croissance 3
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 128.2% | -66.0% | -53.5% | 255.1% | 58.9% | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -28.8% | -17.5% | 37.9% | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 15.3% | · | · | · | · | · | · | · | · | · | · |
Valorisation (TTM) 10
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $14M | $6M | $18M | $39M | $11M | $7M | $6M | $6M | $11M | $1M | $23M | |
| Net Income TTM | $-34M | $-70M | $-73M | $-69M | $-76M | $-64M | $-154M | $-57M | $-84M | $-384M | $-63M | |
| Market Cap | $926M | $621M | $425M | $367M | $564M | $318M | · | $213M | $278M | $134M | · | |
| P/E | -28.3 | -8.6 | -5.7 | -5.1 | -4.7 | -3.5 | -2.1 | -3.2 | -3.2 | -0.3 | -3.2 | |
| P/S | 65.8 | 100.7 | 23.4 | 9.4 | 51.3 | 46.0 | · | 35.8 | 26.0 | 90.1 | · | |
| P/B | 12.1 | 6.4 | 4.0 | 2.7 | 3.3 | 3.1 | · | 1.1 | 1.5 | 0.7 | · | |
| P / Tangible Book | 12.1 | 6.4 | 4.0 | 2.7 | 3.3 | 3.1 | · | · | · | · | · | |
| P / Cash Flow | -23.4 | -9.6 | -4.9 | -10.4 | -8.4 | -6.2 | · | -3.1 | -5.7 | -2.3 | · | |
| P / FCF | -23.4 | -9.6 | -4.9 | -10.2 | -8.3 | -6.2 | · | -3.1 | -5.0 | -2.2 | · | |
| Earnings Yield | -3.5% | -11.6% | -17.6% | -19.7% | -21.3% | -28.2% | -47.5% | -31.6% | -30.9% | -295.5% | -31.0% |
Compte de résultat 16
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1M | $179M | $1M | $529.0K | $11M | $2M | $2M | $1M | $2M | $2M | $2M | $5M | $5M | $7M | $6M | $6M | |
| R&D Expense | $3M | $4M | $5M | $6M | $5M | $9M | $9M | $14M | $16M | $15M | $18M | $20M | $18M | $18M | $23M | $20M | |
| SG&A Expense | $4M | $6M | $4M | $3M | $3M | $6M | $5M | $5M | $8M | $5M | $5M | $6M | $6M | $6M | $4M | $3M | |
| Operating Expenses | $7M | $10M | $6M | $9M | $9M | $27M | $16M | $23M | $23M | $21M | $23M | $26M | $23M | $24M | $29M | $24M | |
| Operating Income | $-6M | $169M | $-5M | $-9M | $1M | $-26M | $-14M | $-21M | $-22M | $-19M | $-21M | $-22M | $-18M | $-17M | $-23M | $-18M | |
| Interest Expense | · | · | · | · | · | · | · | · | $34.0K | $44.0K | · | $46.0K | $171.0K | $198.0K | $309.0K | $429.0K | |
| Interest Income | $842.0K | $815.0K | $877.0K | $952.0K | $1M | $1M | $1M | $2M | $2M | $2M | $1M | $1M | $1M | $1M | $943.0K | $694.0K | |
| Other Non-op | $821.0K | $787.0K | $2M | $917.0K | $1M | $1M | $1M | $2M | $2M | $1M | $1M | $1M | $1M | $1M | $630.0K | $244.0K | |
| Pretax Income | · | · | · | · | · | · | · | · | · | · | · | $-20M | $-17M | $-16M | · | $-18M | |
| Income Tax | $0 | $0 | · | · | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-5M | $170M | $-4M | $-8M | $3M | $-25M | $-13M | $-20M | $-20M | $-18M | $-19M | $-20M | $-17M | $-16M | $-22M | $-18M | |
| EPS (Basic) | $-0.03 | $0.88 | $-0.01 | $-0.04 | $0.01 | $-0.13 | $-0.07 | $-0.10 | $-0.11 | $-0.10 | $-0.12 | $-0.12 | $-0.10 | $-0.10 | $-0.13 | $-0.12 | |
| EPS (Diluted) | $-0.03 | $0.87 | $-0.01 | $-0.04 | $0.01 | $-0.13 | $-0.07 | $-0.10 | $-0.11 | $-0.10 | $-0.12 | $-0.12 | $-0.10 | $-0.10 | $-0.13 | $-0.12 | |
| Shares (Basic) | 197,470,724 | 193,768,641 | -382,437,717 | 191,778,950 | 191,551,282 | 190,707,085 | -367,055,361 | 188,997,194 | 188,041,489 | 175,625,552 | -329,259,017 | 167,512,708 | 166,063,284 | 161,643,404 | -297,234,228 | 150,995,191 | |
| Shares (Diluted) | 197,470,724 | 195,214,067 | -383,286,168 | 191,778,950 | 192,399,733 | 190,707,085 | -367,055,361 | 188,997,194 | 188,041,489 | 175,625,552 | -329,259,017 | 167,512,708 | 166,063,284 | 161,643,404 | -297,234,228 | 150,995,191 | |
| EBITDA | $-6M | $169M | · | $-9M | $1M | $-25M | · | $-21M | $-22M | $-19M | · | $-22M | $-18M | $-17M | · | $-18M |
Bilan 22
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $19M | $24M | $18M | $22M | $37M | $37M | $36M | $32M | $63M | $43M | $26M | $18M | $27M | $41M | $31M | $24M | |
| Short-term Investments | · | · | $73M | · | · | · | $86M | · | · | · | $100M | · | · | · | $116M | · | |
| Receivables | $369.0K | $1M | $1M | $905.0K | $1M | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $3M | $3M | $1M | $2M | |
| Prepaid Expense | $2M | $2M | $2M | $3M | $4M | $3M | $2M | $3M | $4M | $4M | $4M | $5M | $4M | $3M | $3M | $5M | |
| Current Assets | $274M | $277M | $94M | $97M | $103M | $117M | $127M | $133M | $148M | $136M | $132M | $142M | $159M | $153M | $151M | $141M | |
| PP&E (Net) | $10.0K | $22.0K | $32.0K | $137.0K | $148.0K | $168.0K | $3M | $4M | $4M | $4M | $5M | $5M | $5M | $5M | $5M | $5M | |
| PP&E (Gross) | · | · | $245.0K | · | · | · | $16M | · | · | · | $17M | · | · | · | $16M | · | |
| Accum. Depreciation | $235.0K | $224.0K | $213.0K | $13M | $13M | $13M | $13M | $13M | $13M | $12M | $12M | $12M | $11M | $11M | $11M | $10M | |
| Other Non-current Assets | $132.0K | $131.0K | $130.0K | $131.0K | $0 | $34.0K | $34.0K | · | · | · | $0 | $3.0K | $11.0K | $62.0K | $103.0K | $167.0K | |
| Total Assets | $274M | $277M | $95M | $98M | $103M | $117M | $132M | $140M | $160M | $150M | $144M | $159M | $177M | $191M | $195M | $204M | |
| Accounts Payable | $3M | $4M | $5M | $5M | $5M | $12M | $8M | $8M | $11M | $8M | $10M | $10M | $9M | $10M | $16M | $12M | |
| Current Liabilities | $3M | $5M | $6M | $5M | $5M | $19M | $16M | $19M | $23M | $20M | $22M | $22M | $25M | $25M | $33M | $28M | |
| Capital Leases | $0 | $0 | $199.0K | $391.0K | $575.0K | $626.0K | $806.0K | $978.0K | $1M | $1M | $1M | $1M | $2M | $2M | $2M | $2M | |
| Total Liabilities | $15M | $17M | $18M | $20M | $20M | $38M | $34M | $34M | $38M | $36M | $38M | $39M | $42M | $47M | $59M | $58M | |
| Long-term Debt | $0 | $0 | $0 | $0 | $0 | $0 | · | $0 | $0 | $0 | · | $0 | $0 | $0 | · | $0 | |
| Common Stock | $1.45B | $1.44B | $1.42B | $1.42B | $1.42B | $1.42B | $1.41B | $1.41B | $1.40B | $1.38B | $1.35B | $1.35B | $1.34B | $1.34B | $1.32B | $1.31B | |
| Paid-in Capital | $74M | $74M | $83M | $83M | $83M | $82M | $82M | $81M | $82M | $80M | $81M | $80M | $77M | $74M | $72M | $71M | |
| Retained Earnings | $-1.22B | $-1.21B | $-1.38B | $-1.38B | $-1.37B | $-1.37B | $-1.35B | $-1.33B | $-1.31B | $-1.29B | $-1.28B | $-1.26B | $-1.24B | $-1.22B | $-1.20B | $-1.18B | |
| AOCI | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-49M | $-49M | $-50M | $-50M | $-51M | |
| Stockholders' Equity | $259M | $260M | $77M | $77M | $83M | $79M | $97M | $107M | $122M | $115M | $106M | $119M | $135M | $144M | $137M | $146M | |
| Liabilities + Equity | $274M | $277M | $95M | $98M | $103M | $117M | $132M | $140M | $160M | $150M | $144M | $159M | $177M | $191M | $195M | $204M | |
| Shares Outstanding | 197,634,118 | 196,947,757 | 192,531,225 | 191,953,665 | 191,641,511 | 191,481,474 | 189,963,492 | 189,438,135 | 188,739,044 | 180,192,227 | 169,867,414 | 167,695,247 | 166,922,739 | 165,132,193 | 157,455,363 | 152,711,702 |
Flux de trésorerie 11
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $11.0K | $11.0K | · | $11.0K | $11.0K | $330.0K | · | $336.0K | $356.0K | $355.0K | · | $369.0K | $342.0K | $334.0K | · | $343.0K | |
| Stock-based Comp | $2M | $1M | $1M | $1M | $864.0K | $4M | $2M | $2M | $3M | $2M | $2M | $2M | $3M | $2M | $2M | $2M | |
| Restructuring | $0 | $0 | $-12M | $98.0K | $165.0K | $12M | $95.0K | $4M | $0 | $0 | $0 | $0 | · | · | · | · | |
| Other Non-cash | · | $-179M | · | · | · | $7M | · | · | · | $-4M | · | · | · | $-13M | · | · | |
| Operating Cash Flow | $-6M | $-8M | $-5M | $-6M | $-16M | $-13M | $-10M | $-21M | $-15M | $-19M | $-17M | $-22M | $-20M | $-27M | $-17M | $-19M | |
| CapEx | · | · | $0 | $0 | $0 | $0 | $86.0K | $0 | $1.0K | $95.0K | $0 | $32.0K | $859.0K | $117.0K | $134.0K | $91.0K | |
| Investing Cash Flow | $-2M | $2M | $-1M | $-10M | $16M | $11M | $13M | $-12M | $10M | $12M | $22M | $10M | $1M | $17M | $13M | $-14M | |
| Financing Cash Flow | $3M | $12M | $2M | $844.0K | $453.0K | $3M | $1M | $2M | $24M | $24M | $4M | $2M | $5M | $20M | $11M | $9M | |
| Net Change in Cash | $-5M | $6M | $-4M | $-15M | $336.0K | $746.0K | $4M | $-31M | $20M | $17M | $9M | $-10M | $-13M | $10M | $7M | $-23M | |
| Free Cash Flow | · | · | · | · | · | $-13M | · | · | · | $-19M | · | · | · | $-27M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | · | · | · | · | $-28M | · | · |
Rentabilité 7
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -588.2% | 94.3% | · | -1636.9% | 13.9% | -1456.9% | · | -1601.2% | -1250.5% | -1263.9% | · | -462.8% | -395.3% | -260.4% | · | -299.2% | |
| Net Margin | -507.2% | 94.7% | · | -1463.5% | 23.5% | -1390.4% | · | -1472.5% | -1146.9% | -1166.8% | · | -431.6% | -367.5% | -244.3% | · | -295.1% | |
| Pretax Margin | · | · | · | · | · | · | · | · | · | · | · | -431.6% | -367.5% | -244.3% | · | -295.1% | |
| EBITDA Margin | -588.2% | 94.3% | · | -1636.9% | 13.9% | -1438.2% | · | -1601.2% | -1250.5% | -1240.7% | · | -462.8% | -395.3% | -255.4% | · | -299.2% | |
| ROA | -2.7% | 86.1% | · | -6.5% | 1.9% | -18.4% | · | -13.2% | -11.8% | -10.5% | · | -11.1% | -8.7% | -7.6% | · | -9.5% | |
| ROE | -3.0% | 100.0% | · | -8.4% | 2.5% | -25.3% | · | -17.4% | -15.4% | -13.8% | · | -15.2% | -11.9% | -10.5% | · | -12.8% | |
| ROIC | · | · | · | · | · | · | · | · | · | · | · | -18.1% | -13.7% | -12.1% | · | -12.2% |
Liquidité et Solvabilité 3
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 81.4 | 54.3 | · | 18.8 | 20.5 | 6.0 | · | 7.0 | 6.6 | 6.7 | · | 6.3 | 6.5 | 6.1 | · | 5.1 | |
| Quick Ratio | 5.8 | 4.9 | · | 4.5 | 7.7 | 2.0 | · | 1.8 | 2.9 | 2.2 | · | 0.9 | 1.2 | 1.7 | · | 0.9 | |
| Interest Coverage | · | · | · | · | · | · | · | · | -634.8 | -440.1 | · | -468.7 | -107.5 | -87.9 | · | -41.5 |
Efficacité 2
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.9 | · | 0.0 | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | 1.5 | 143.6 | · | 0.4 | 7.7 | 1.1 | · | 0.7 | 0.8 | 0.6 | · | 2.3 | 2.0 | 3.4 | · | 3.4 |
Valorisation (TTM) 10
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $191M | $192M | · | $14M | $16M | $6M | · | $9M | $13M | $18M | · | $22M | $32M | $39M | · | $36M | |
| Net Income TTM | $159M | $140M | · | $-49M | $-62M | $-82M | · | $-77M | $-75M | $-71M | · | $-71M | $-65M | $-64M | · | $-67M | |
| Market Cap | $949M | $886M | · | $871M | $592M | $668M | · | $729M | $583M | $465M | · | $340M | $384M | $500M | · | $292M | |
| P/E | 5.9 | 6.3 | · | -17.5 | -9.4 | -7.9 | · | -9.0 | -7.2 | -6.1 | · | -4.6 | -5.5 | -7.0 | · | -3.4 | |
| P/S | 5.0 | 4.6 | · | 60.6 | 38.0 | 105.1 | · | 78.8 | 46.4 | 26.5 | · | 15.5 | 12.2 | 12.7 | · | 8.1 | |
| P/B | 3.7 | 3.4 | · | 11.3 | 7.1 | 8.4 | · | 6.8 | 4.8 | 4.1 | · | 2.9 | 2.9 | 3.5 | · | 2.0 | |
| P / Tangible Book | 3.7 | 3.4 | · | 11.3 | 7.1 | 8.4 | · | 6.8 | 4.8 | 4.1 | · | 2.9 | 2.9 | 3.5 | · | 2.0 | |
| P / Cash Flow | · | -109.3 | · | · | · | -49.9 | · | · | · | -24.1 | · | · | · | -18.3 | · | · | |
| P / FCF | · | · | · | · | · | -49.9 | · | · | · | -24.0 | · | · | · | -18.2 | · | · | |
| Earnings Yield | 16.9% | 15.8% | · | -5.7% | -10.7% | -12.6% | · | -11.2% | -13.9% | -16.3% | · | -21.7% | -18.3% | -14.2% | · | -29.8% |
États financiers Compte de résultat, bilan, flux de trésorerie — annuel, sur les 5 dernières années
Compte de résultat
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Revenu | $14M | $6M | $18M | $39M | $11M |
| Marge d'exploitation % | -271.0% | -1236.7% | -430.5% | -167.8% | -669.1% |
| Résultat net | $-34M | $-70M | $-73M | $-69M | $-76M |
| BPA dilué | $-0.17 | $-0.38 | $-0.44 | $-0.46 | $-0.83 |
Bilan
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Ratio de liquidité | 15.7 | 8.2 | 5.9 | 4.6 | 14.3 |
| Ratio de liquidité réduite | 15.5 | 8.0 | 5.7 | 4.5 | 13.9 |
Flux de trésorerie
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Flux de trésorerie libre | $-40M | $-65M | $-87M | $-36M | $-68M |
Dernières actualités Actualités récentes mentionnant cette entreprise
Mes métriques Votre watchlist personnelle — lignes sélectionnées de Fondamentaux Complets
📊
Choisissez les indicateurs qui vous importent — cliquez sur le ➕ à côté de n'importe quelle ligne dans Fondamentaux Complets ci-dessus.
Votre sélection est enregistrée et vous suit sur tous les tickers.
Détenteurs institutionnels (13F) 191 déclarants · $496.0M total · Au 30 juin 2026
Institutions qui déclarent détenir cette action dans leur Formulaire SEC 13F trimestriel. Uniquement les positions longues ; un même déclarant peut apparaître deux fois pour des jambes d'options distinctes. Les jambes put/call compensatoires importantes reflètent généralement la tenue de marché ou un inventaire couvert, pas une conviction directionnelle.
Activité institutionnelle — Q2 2026 vs trimestre précédent
| Nouvelles positions | Positions clôturées | Augmenté | Diminué | Variation nette des actions |
|---|---|---|---|---|
| 41 (+15 vs T. préc.) | 22 (-8 vs T. préc.) | 55 (+10 vs T. préc.) | 44 (-8 vs T. préc.) | +14.8M |
Comparé à Q1 2026. Les dépôts de formulaire 13F de la SEC sont dus dans les 45 jours suivant la fin du trimestre, plus une courte période tampon pour les déposants tardifs — les trimestres encore dans cette fenêtre sont ignorés au profit de la paire la plus récente entièrement déclarée.
| Institution | Valeur | Actions | % de 13F suivies | Type |
|---|---|---|---|---|
| Two Seas Capital LP | $91 658 798 | 19 095 583 | 18,48% | Actions |
| Whitefort Capital Management, LP | $75 812 453 | 15 794 261 | 15,28% | Actions |
| VANGUARD GROUP INC | $38 412 670 | 7 986 002 | 7,74% | Actions |
| STATE STREET CORP | $37 772 059 | 7 869 179 | 7,62% | Actions |
| Rubric Capital Management LP | $36 158 098 | 7 532 937 | 7,29% | Actions |
| VANGUARD CAPITAL MANAGEMENT LLC | $33 651 259 | 7 010 679 | 6,78% | Actions |
| GEODE CAPITAL MANAGEMENT, LLC | $16 983 987 | 3 537 471 | 3,42% | Actions |
| BlackBarn Capital Partners LP | $12 000 000 | 2 500 000 | 2,42% | Actions |
| Woodline Partners LP | $10 952 909 | 2 281 856 | 2,21% | Actions |
| GOLDMAN SACHS GROUP INC | $8 545 829 | 1 780 381 | 1,72% | Actions |
| Jefferies Financial Group Inc. | $8 216 026 | 1 711 672 | 1,66% | Actions |
| NOMURA HOLDINGS INC | $7 857 989 | 1 637 081 | 1,58% | Actions |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $7 398 998 | 1 541 458 | 1,49% | Actions |
| BANK OF AMERICA CORP /DE/ | $7 169 851 | 1 493 719 | 1,45% | Actions |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $6 869 846 | 1 431 218 | 1,38% | Actions |
| OSAIC HOLDINGS, INC. | $6 469 756 | 1 347 866 | 1,30% | Actions |
| ADAR1 Capital Management, LLC | $6 087 106 | 1 268 147 | 1,23% | Actions |
| Deltroit Asset Management (UK) LLP | $5 760 000 | 1 200 000 | 1,16% | Actions |
| VANGUARD FIDUCIARY TRUST CO | $5 449 738 | 1 135 362 | 1,10% | Actions |
| CITIGROUP INC | $4 175 784 | 869 955 | 0,84% | Actions |
| BANK OF MONTREAL /CAN/ | $3 734 102 | 777 938 | 0,75% | Actions |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $3 123 360 | 650 700 | 0,63% | Actions |
| MACKENZIE FINANCIAL CORP | $2 946 269 | 613 806 | 0,59% | Actions |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $2 889 638 | 602 008 | 0,58% | Actions |
| Western Standard LLC | $2 605 378 | 542 787 | 0,53% | Actions |
| Rangeley Capital, LLC | $2 400 000 | 500 000 | 0,48% | Actions |
| Man Group plc | $2 272 642 | 473 467 | 0,46% | Actions |
| Corbin Capital Partners, L.P. | $2 231 732 | 682 487 | 0,45% | Actions |
| CenterBook Partners LP | $2 136 725 | 445 151 | 0,43% | Actions |
| Freestone Capital Holdings, LLC | $2 124 000 | 442 500 | 0,43% | Actions |
| CITADEL ADVISORS LLC | $1 942 541 | 404 696 | 0,39% | Actions |
| KENNEDY CAPITAL MANAGEMENT LLC | $1 849 430 | 385 298 | 0,37% | Actions |
| Swiss National Bank | $1 375 200 | 286 500 | 0,28% | Actions |
| Ledgewood Wealth Advisors, LLC | $1 336 493 | 278 436 | 0,27% | Actions |
| FMR LLC | $1 277 232 | 266 090 | 0,26% | Actions |
| Susquehanna Portfolio Strategies, LLC | $1 265 688 | 263 685 | 0,26% | Actions |
| Carrera Capital Advisors | $1 234 402 | 257 167 | 0,25% | Actions |
| Quinn Opportunity Partners LLC | $1 225 027 | 255 214 | 0,25% | Actions |
| D. E. Shaw & Co., Inc. | $1 209 614 | 252 003 | 0,24% | Actions |
| STATE OF WISCONSIN INVESTMENT BOARD | $1 161 682 | 242 017 | 0,23% | Actions |
| Campbell & CO Investment Adviser LLC | $1 106 563 | 230 534 | 0,22% | Actions |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1 080 475 | 225 099 | 0,22% | Actions |
| Squarepoint Ops LLC | $999 096 | 208 145 | 0,20% | Actions |
| MARTINGALE ASSET MANAGEMENT L P | $926 880 | 193 100 | 0,19% | Actions |
| RHUMBLINE ADVISERS | $909 224 | 189 423 | 0,18% | Actions |
| STRS OHIO | $810 720 | 168 900 | 0,16% | Actions |
| Bank of New York Mellon Corp | $801 067 | 166 889 | 0,16% | Actions |
| Caption Management, LLC | $720 000 | 150 000 | 0,15% | Option d'achat |
| Caption Management, LLC | $720 000 | 150 000 | 0,15% | Option de vente |
| Hudson Bay Capital Management LP | $720 000 | 150 000 | 0,15% | Actions |
| Wealth Management Associates, Inc. | $710 376 | 147 995 | 0,14% | Actions |
| WELLINGTON MANAGEMENT GROUP LLP | $701 467 | 146 139 | 0,14% | Actions |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $643 433 | 142 985 | 0,13% | Actions |
| ALLIANCEBERNSTEIN L.P. | $631 080 | 140 240 | 0,13% | Actions |
| Connor, Clark & Lunn Investment Management Ltd. | $619 685 | 129 101 | 0,12% | Actions |
| BlackRock, Inc. | $567 398 | 118 208 | 0,11% | Actions |
| Front Row Advisors LLC | $516 035 | 110 500 | 0,10% | Actions |
| BARCLAYS PLC | $499 320 | 104 025 | 0,10% | Actions |
| Rafferty Asset Management, LLC | $490 416 | 102 170 | 0,10% | Actions |
| MetLife Investment Management, LLC | $452 885 | 94 351 | 0,09% | Actions |
| VANGUARD ASSET MANAGEMENT, Ltd | $429 994 | 89 582 | 0,09% | Actions |
| TWO SIGMA INVESTMENTS, LP | $407 933 | 84 986 | 0,08% | Actions |
| JBF Capital, Inc. | $385 349 | 80 281 | 0,08% | Actions |
| Integrated Quantitative Investments LLC | $383 698 | 79 937 | 0,08% | Actions |
| Virtus Investment Advisers, LLC | $368 674 | 76 807 | 0,07% | Actions |
| XTX Topco Ltd | $365 808 | 76 210 | 0,07% | Actions |
| AMERICAN CENTURY COMPANIES INC | $317 832 | 66 215 | 0,06% | Actions |
| Invesco Ltd. | $305 616 | 63 670 | 0,06% | Actions |
| Rockefeller Capital Management L.P. | $302 400 | 63 000 | 0,06% | Actions |
| Creative Planning | $298 133 | 62 111 | 0,06% | Actions |
| JANUS HENDERSON GROUP PLC | $273 746 | 60 900 | 0,06% | Actions |
| Quantinno Capital Management LP | $273 413 | 56 961 | 0,06% | Actions |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $265 118 | 55 233 | 0,05% | Actions |
| Vanguard Global Advisers, LLC | $264 730 | 55 152 | 0,05% | Actions |
| Mitsubishi UFJ Asset Management Co., Ltd. | $255 936 | 53 320 | 0,05% | Actions |
| Jump Financial, LLC | $255 178 | 53 162 | 0,05% | Actions |
| PROFUND ADVISORS LLC | $254 482 | 53 017 | 0,05% | Actions |
| WOLVERINE TRADING, LLC | $248 868 | 55 800 | 0,05% | Option d'achat |
| Police & Firemen's Retirement System of New Jersey | $248 203 | 51 709 | 0,05% | Actions |
| Exome Asset Management LLC | $240 797 | 50 166 | 0,05% | Actions |
| Magnetar Financial LLC | $225 922 | 47 067 | 0,05% | Actions |
| State of New Jersey Common Pension Fund D | $221 602 | 46 167 | 0,04% | Actions |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $212 664 | 44 305 | 0,04% | Actions |
| ALLSTATE CORP | $212 285 | 44 226 | 0,04% | Actions |
| Quadrature Capital Ltd | $201 619 | 42 004 | 0,04% | Actions |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $189 475 | 39 474 | 0,04% | Actions |
| ARIZONA STATE RETIREMENT SYSTEM | $189 110 | 39 398 | 0,04% | Actions |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $175 680 | 36 600 | 0,04% | Option d'achat |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $171 936 | 35 820 | 0,03% | Actions |
| NEW YORK STATE COMMON RETIREMENT FUND | $169 286 | 35 268 | 0,03% | Actions |
| INTECH INVESTMENT MANAGEMENT LLC | $167 208 | 34 835 | 0,03% | Actions |
| Mitsubishi UFJ Trust & Banking Corp | $152 102 | 31 688 | 0,03% | Actions |
| VOYA INVESTMENT MANAGEMENT LLC | $151 070 | 31 473 | 0,03% | Actions |
| China Universal Asset Management Co., Ltd. | $150 902 | 31 438 | 0,03% | Actions |
| Vanguard Investments Australia, Ltd. | $150 182 | 31 288 | 0,03% | Actions |
| KLP KAPITALFORVALTNING AS | $148 320 | 30 900 | 0,03% | Actions |
| Premier Path Wealth Partners, LLC | $144 000 | 30 000 | 0,03% | Actions |
| BNP PARIBAS FINANCIAL MARKETS | $139 675 | 29 099 | 0,03% | Actions |
| SHERBROOKE PARK ADVISERS LLC | $134 627 | 27 989 | 0,03% | Actions |
| EntryPoint Capital, LLC | $134 112 | 27 940 | 0,03% | Actions |
Initiés de la société 25 initiés · 13 dirigeants · 11 administrateurs
| Dirigeant | Rôle | Dernière activité | Actions détenues | Achats 12m | Ventes 12m | Net 12m |
|---|---|---|---|---|---|---|
| William H. Collier | President and CEO | 24 juin 2019 A | — | 0 | 0 | $0 |
| Mark J. Murray | President and CEO | 1 mars 2019 A | 341 396 | 0 | 0 | $0 |
| David C Hastings | Chief Financial Officer | 1 mars 2019 A | — | 0 | 0 | $0 |
| Bruce Cousins | EVP & Chief Financial Officer | 24 mars 2017 A | — | 0 | 0 | $0 |
| Gaston Picchio | Chief Development Officer | 1 mars 2019 A | — | 0 | 0 | $0 |
| Elizabeth Howard | Executive VP & General Counsel | 1 mars 2019 A | — | 0 | 0 | $0 |
| Michael J. Mcelhaugh | Chief Business Officer | 1 mars 2019 A | — | 0 | 0 | $0 |
| Michael J. Sofia | Chief Scientific Officer | 1 mars 2019 A | 1 503 403 | 0 | 0 | $0 |
| Koert Vandenenden | Chief Accounting Officer | 11 décembre 2018 A | — | 0 | 0 | $0 |
| William T. Symonds | Chief Development Officer | 16 avril 2018 A | — | 0 | 0 | $0 |
| Peter Lutwyche | Chief Technology Officer | 24 mars 2017 A | — | 0 | 0 | $0 |
| Michael J. Abrams | Managing Director | 16 août 2016 M | 42 097 | 0 | 0 | $0 |
| Mark Kowalski | Sr VP & Chief Medical Officer | 15 mars 2016 A | — | 0 | 0 | $0 |
| Roger Sawhney | Administrateur | 8 juin 2026 A | — | 0 | 0 | $0 |
| Robert A Beardsley | Administrateur | 8 juin 2026 A | — | 0 | 0 | $0 |
| Frank Torti | Administrateur | 26 novembre 2018 A | — | 0 | 0 | $0 |
| Vivek Ramaswamy | Administrateur | 19 juin 2018 A | — | 0 | 0 | $0 |
| Keith S Manchester | Administrateur | 19 juin 2018 A | — | 0 | 0 | $0 |
| Daniel D Burgess | Administrateur | 19 juin 2018 A | — | 0 | 0 | $0 |
| Herbert J Conrad | Administrateur | 19 juin 2018 A | — | 0 | 0 | $0 |
| Richard C Henriques JR | Administrateur | 19 juin 2018 A | 1 000 | 0 | 0 | $0 |
| Frank Karbe | Administrateur | 21 juin 2017 A | — | 0 | 0 | $0 |
| Roivant Sciences Ltd. | Détenteur de 10% | 18 octobre 2021 C | 38 847 462 | 0 | 0 | $0 |
| Andrew Lo | Détenteur de 10% | 12 janvier 2018 P | — | 0 | 0 | $0 |
| Patrick Machado | Détenteur de 10% | 12 janvier 2018 P | — | 0 | 0 | $0 |
Initiés issus des déclarations SEC Form 3/4/5 ; net = uniquement P/S de marché
Activistes et détenteurs de 5%+ 8 participations
Investisseurs ayant déposé un Schedule 13D auprès de la SEC — détention effective supérieure à 5% avec l'intention d'influencer l'émetteur (participations activistes, campagnes pour le conseil d'administration, fusions-acquisitions). Chaque ligne montre le dernier état connu de la position du déposant.
| Déclarant | Déposé | Participation | Statut | Objectif | Dépôt |
|---|---|---|---|---|---|
| Whitefort Capital Master Fund, LP, Whitefort Capital GP, LLC, Whitefort Capital Management, LP, Whitefort Capital Management GP, LLC, David Salanic, Joseph Kaplan ×5 dépôts | 28 avril 2026 | 8,00% | Amendement | — | SEC |
| Roivant Sciences Ltd. ×14 dépôts | 25 février 2025 | 20,50% | Amendement | — | SEC |
| Patrick Machado ×4 dépôts | 17 juillet 2019 | — | Dépôt initial | — | SEC |
| Dr. Andrew Lo ×5 dépôts | 17 juillet 2019 | — | Dépôt initial | — | SEC |
| SVF Investments (UK) Limited, SVF Holdings (UK) LLP, SoftBank Vision Fund L.P., SVF GP (Jersey) Limited ×4 dépôts | 12 juillet 2019 | — | Dépôt initial | — | SEC |
| QVT Financial LP, QVT Financial GP LLC, QVT Family Office Fund LP, QVT Associates GP LLC ×6 dépôts | 12 juillet 2019 | — | Dépôt initial | — | SEC |
| Dexxon Holdings Ltd., Dexcel Pharma Technologies Ltd., Dan Oren ×6 dépôts | 12 juillet 2019 | — | Dépôt initial | — | SEC |
| Viking Global Investors LP, Viking Global Performance LLC, Viking Global Equities LP, Viking Global Equities II LP, VGE III Portfolio Ltd., Viking Global Equities Master Ltd., Viking Long Fund GP LLC, Viking Long Fund Master Ltd., Viking Global Opportunities GP LLC, Viking Global Opportunities Portfolio GP LLC, Viking Global Opportunities Illiquid Investments Sub-Master LP, O. Andreas Halvorsen, David C. Ott, Rose S. Shabet ×7 dépôts | 12 juillet 2019 | — | Dépôt initial | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Détention d'ETF Détenu par 34 ETFs
Le poids reflète uniquement les participations directes en actions (N-PORT) ; les fonds à effet de levier ou basés sur des dérivés peuvent détenir une exposition supplémentaire aux swaps non indiquée.
| Fonds | Poids | Unités | Au | Source |
|---|---|---|---|---|
| BBC · ETFis Series Trust I | 0,66% | 58 600 NS | 30 avril 2026 | N-PORT |
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,50% | 24 523 SH | 8 août 2026 | Quotidien |
| IWC · iShares Trust | 0,17% | 546 359 SH | 8 août 2026 | Quotidien |
| LABU · Direxion Shares ETF Trust | 0,11% | 132 235 NS | 30 avril 2026 | N-PORT |
| SMMV · iShares Trust | 0,10% | 62 236 SH | 8 août 2026 | Quotidien |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,06% | 10 748 SH | 8 août 2026 | Quotidien |
| IBB · iShares Trust | 0,06% | 1 164 301 SH | 8 août 2026 | Quotidien |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,05% | 172 487 SH | 8 août 2026 | Quotidien |
| IWO · iShares Trust | 0,04% | 1 441 824 SH | 8 août 2026 | Quotidien |
| BIB · ProShares Trust | 0,04% | 7 110 NS | 31 mai 2026 | N-PORT |
| GSSC · Goldman Sachs ETF Trust | 0,03% | 64 366 NS | 31 mai 2026 | N-PORT |
| IWM · iShares Trust | 0,02% | 4 026 921 SH | 8 août 2026 | Quotidien |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,02% | 925 044 SH | 8 août 2026 | Quotidien |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,02% | 122 366 SH | 8 août 2026 | Quotidien |
| RSSL · Global X Funds | 0,02% | 65 520 NS | 30 avril 2026 | N-PORT |
| ITWO · ProShares Trust | 0,02% | 7 126 NS | 31 mai 2026 | N-PORT |
| SCHA · SCHWAB STRATEGIC TRUST | 0,01% | 734 401 NS | 31 mai 2026 | N-PORT |
| ISCG · iShares Trust | 0,01% | 24 628 SH | 8 août 2026 | Quotidien |
| ISCB · iShares Trust | 0,01% | 6 673 SH | 8 août 2026 | Quotidien |
| UWM · ProShares Trust | 0,01% | 5 554 NS | 31 mai 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,01% | 1 810 587 SH | 8 août 2026 | Quotidien |
| VHT · VANGUARD WORLD FUND | 0,01% | 430 244 SH | 8 août 2026 | Quotidien |
| FHLC · FIDELITY COVINGTON TRUST | 0,01% | 64 437 NS | 30 avril 2026 | N-PORT |
| ISCV · iShares Trust | 0,01% | 13 314 SH | 8 août 2026 | Quotidien |
| WSML · iShares Trust | 0,01% | 11 503 SH | 8 août 2026 | Quotidien |
| URTY · ProShares Trust | 0,01% | 5 639 NS | 31 mai 2026 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,00% | 5 309 NS | 31 mai 2026 | N-PORT |
| HDG · ProShares Trust | 0,00% | 141 NS | 31 mai 2026 | N-PORT |
| ITOT · iShares Trust | 0,00% | 266 009 SH | 8 août 2026 | Quotidien |
| IWV · iShares Trust | 0,00% | 49 253 SH | 8 août 2026 | Quotidien |
| SCHB · SCHWAB STRATEGIC TRUST | 0,00% | 86 163 NS | 31 mai 2026 | N-PORT |
| AVSC · AMERICAN CENTURY ETF TRUST | 0,00% | 4 760 NS | 31 mai 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 5 034 547 SH | 8 août 2026 | Quotidien |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 13 683 SH | 8 août 2026 | Quotidien |